Projects

• NEWTBVAC
• TBVAC
• INYVAX
• TRANSVAC
• ADITEC
• TBTEA
• MYCOWALC
• ESI TBVI
• TBVI Advocacy & Fundraising

1. TBVI »
2. Projects »
3. ADITEC

Accelerating the development of novel and powerful immunisation technologies

Aditec is a collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 12 countries and 42 research partners collaborate in the ADITEC (Advanced Immunization Technologies) project, that received a 30 Million euro grant from the European Union. The project focusses on tuberculosis, influenza and herpes.

Aditec comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. All possible aspects of vaccination, from basic research, new technologies to clinical trials and public health, are covered.

Aditec is a 5-year project and is funded by the EU 7^th Framework Programme.

The following partners form the research consortium:

Sclavo Vaccines Association (Italy), Statens Serum Institut (Denmark), St George University of London (UK), Max Planck Institute for Infection Biology (Germany), Institute Pasteur (France), University of Oxford (UK), University of Siena (Italy), University of Geneva (Switzerland), Novartis Vaccines and Diagnostics s.r.l. (Italy),Intercell (Austria), University of Goteborg (Germany), Leiden University and Medical Centre (The Netherlands), Emory University (Atlanta, USA), Tuberculosis Vaccine Initiative (The Netherlands), Institute for Biomedical Aging Research (Austria), Infectious Disease Research Institute (Seattle, USA), Utrecht University (The Netherlands), Fondazione Humanitas per la Ricerca (Italy), Fondazione per l’Istituto di Ricerca in Biomedicina (Switzerland), Istituto Superiore di Sanità (Italy), Kings College London (UK), World Health Organization (Switzerland), French Atomic Energy (France), Institut de Biologie et Chimie des Protéines (France), Erasmus Medical Center (The Netherlands), ALTA s.r.l.u (Italy), Medicine in need (USA), deCODE Genetics (Iceland), Okairos (Italy), Sigmoid Pharma (Ireland), Vaccibody (Norway), Pevion Biotech (Switzerland), Duotol AB (Sweden), Crossbeta Biosciences (The Netherlands), Microbiotec srl (Italy), ArenaVax (Austria), Xbrane Bioscience AB (Sweden), Bioneedle Group (The Netherlands), Novartis Vaccines Institute for Global Health s.r.l (Italy), National Institute for Biological Standards and Control (UK), Seattle Biomedical Research Institute (USA), Imperial College London (UK).